Objectives:
A congenital loss of cytotoxic lymphocyte activity leads to a potentially fatal immune dysregulation, familial haemophagocytic lymphohistiocytosis. Until recently, this disease was uniformly associated with infants or very young children, but it appears now that the onset may be delayed for decades. As a result, some adults are being mis- or under-diagnosed because of their 'atypical' symptoms that are not recognised as immunodeficiency. The clinical picture and histopathology can overlap with those of haematologic malignancy, further complicating the diagnostic thought process. The spectrum of atypical symptoms is poorly defined, and therefore, it is important to describe these cases and the attendant immunological and cellular changes associated with familial haemophagocytic lymphohistiocytosis, in order to improve diagnosis and prevent unintended consequences of symptomatic therapies.
Methods:
A 45-year-old patient presented with suspected T-cell lymphoma and was treated with combination chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisolone) supplemented with granulocyte-colony stimulating factor (G-CSF). To mobilise stem cells for autologous transplantation, the patient was then treated with high-dose G-CSF and rapidly developed haemophagocytic lymphohistiocytosis. Symptoms resolved temporarily with intensive immunosuppression with alemtuzumab and durably with a subsequent allograft.
Results:
The patient was found to be a carrier of bi-allelic mutations in the STXBP2 protein that is essential for cytotoxic lymphocyte function, and the initial diagnosis has been revised as familial haemophagocytic lymphohistiocytosis.
Conclusion:
This case highlights the difficulty in distinguishing atypical/late-onset familial haemophagocytic lymphohistiocytosis from a malignant process as well as a possible exacerbation of the disease with G-CSF therapy.